|
|
| (30 intermediate revisions by 2 users not shown) |
| Line 1: |
Line 1: |
| {{DrugProjectFormSinglePage
| | #REDIRECT [[Enalapril]] |
| |authorTag={{AZ}}, {{AM}}
| |
| |genericName=Epaned, Vasotec
| |
| |aOrAn=an
| |
| |drugClass=Angiontensin converting enzyme inhibitor
| |
| |indication=[[hypertension]], [[heart failure]], left ventricular dysfunction after [[myocardial infarction]], [[diabetic nephropathy]]
| |
| |hasBlackBoxWarning=Yes
| |
| |adverseReactions=Hyperkalemia (1% to 3.8% ), Dizziness (4.3% to 7.9% ), Serum blood urea nitrogen raised (0.2% to 11% ), Serum creatinine raised (0.2% to 11% ), Fatigue (3% )
| |
| |blackBoxWarningTitle=USE IN PREGNANCY
| |
| |blackBoxWarningBody=<i><span style="color:#FF0000;">Condition Name:</span>Fetal Death</i> When used in pregnancy during the second and third trimesters, ACE inhibitors can cause injury and even death to the developing fetus. When pregnancy is detected, enalapril maleate should be discontinued as soon as possible. See WARNINGS, Fetal / Neonatal Morbidity and Mortality.
| |
| |fdaLIADAdult=<h4>Condition 1</h5>
| |
| | |
| * Dosing Information
| |
| | |
| :: (Dosage)
| |
| }}
| |